Analyzing Hospital Transfers Using INTERACT Acute Care Transfer Tools: Lessons from MOQI - American Geriatric Society

OBJECTIVES

We explored the differences in potentially avoidable/unavoidable hospital transfers in a retrospective analysis of Interventions to Reduce Acute Care Transfers (INTERACT) Acute Transfer Tools (ACTs) completed by advanced practice registered nurses (APRNs) working in the Missouri Quality Improvement (QI) Initiative (MOQI).

DESIGN

Cross‐sectional descriptive study of 3996 ACTs for 32.5 calendar months from 2014 to 2016. Univariate analyses examined differences between potentially avoidable vs unavoidable transfers. Multivariate logistic regression analysis of candidate factors identified those contributing to avoidable transfers.

Setting

Sixteen nursing homes (NHs), ranging from 120 to 321 beds, in urban, metro, and rural communities within 80 miles of a large midwestern city.

PARTICIPANTS

A total of 5168 residents with a median age of 82 years.

MEASUREMENTS

Data from 3946 MOQI‐adapted ACTs.

RESULTS

A total of 54% of hospital transfers were identified as avoidable. QI opportunities related to avoidable transfers were earlier detection of new signs/symptoms (odds ratio [OR] = 2.35; 95% confidence interval [CI] = 1.61‐3.42; P < .001); discussions of resident/family preference (OR = 2.12; 95% CI = 1.38‐3.25; P < .001); advance directive/hospice care (OR = 2.25; 95% CI = 1.33‐3.82; P = .003); better communication about condition (OR = 4.93; 95% CI = 3.17‐7.68; P < .001); and condition could have been managed in the NH (OR = 16.63; 95% CI = 10.9‐25.37; P < .001). Three factors related to unavoidable transfers were bleeding (OR = .59; 95% CI = .46‐.77; P < .001), nausea/vomiting (OR = .7; 95% CI = .54‐.91; P = .007), and resident/family preference for hospitalization (OR = .79; 95% CI = .68‐.93; P = .003).

CONCLUSION

Reducing avoidable hospital transfers in NHs requires challenging assumptions about what is avoidable so QI efforts can be directed to improving NH capacity to manage ill residents. The APRNs served as the onsite coaches in the use and adoption of INTERACT. Changes in health policy would provide a revenue stream to support APRN presence in NH, a role that is critical to improving resident outcomes by increasing staff capacity to identify illness and guide system change.

from Wiley: Journal of the American Geriatrics Society: Table of Contents http://bit.ly/2IeDmS5
via IFTTT

Statement on FDA’s scientific work to understand per- and polyfluoroalkyl substances (PFAS) in food, and findings from recent FDA surveys - FDA Press Releases

FDA’s scientific work to understand per- and polyfluoroalkyl substances (PFAS) in food, and findings from recent FDA surveys

from FDA Press Releases RSS Feed http://bit.ly/2X2JeGe
via IFTTT

FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettes - FDA Press Releases

FDA finalizes guidance for manufacturers submitting premarket tobacco product applications for electronic nicotine delivery systems, such as e-cigarettes or “vapes.”

from FDA Press Releases RSS Feed http://bit.ly/2I74UbU
via IFTTT

Chromones with lipoprotein oxidation inhibitory activity from an endophytic fungus Alternaria brassicae JS959 derived from Vitex rotundifolia - Journal of Antibiotics

The Journal of Antibiotics, Published online: 11 June 2019; doi:10.1038/s41429-019-0198-4

Chromones with lipoprotein oxidation inhibitory activity from an endophytic fungus Alternaria brassicae JS959 derived from Vitex rotundifolia

from The Journal of Antibiotics - Issue - nature.com science feeds https://go.nature.com/2Wtr3VQ
via IFTTT

FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma - FDA Press Releases

FDA approved Polivy in combination with the chemotherapy bendamustine and a rituximab product to treat adult patients with diffuse large B-cell lymphoma that has progressed or returned after at least two prior therapies.

from FDA Press Releases RSS Feed http://bit.ly/2F4VXho
via IFTTT

FDA permits marketing of first medical device for relief of pain associated with irritable bowel syndrome in patients 11-18 years of age - FDA Press Releases

FDA permits marketing of the first medical device to aid in the reduction of functional abdominal pain in patients 11-18 years of age with irritable bowel syndrome (IBS) when combined with other therapies for IBS.

from FDA Press Releases RSS Feed http://bit.ly/2EXR9tQ
via IFTTT

Remarks on World Food Safety Day: ‘Food Safety Is Everyone’s Business’ - FDA Press Releases

Remarks from Deputy Commissioner Frank Yiannas on World Food Safety Day

from FDA Press Releases RSS Feed http://bit.ly/2WA8HYc
via IFTTT